Euclidean Capital’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Euclidean Capital’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-554,325	Closed	-$18.7M	–	16
2021 Q2	$18.7M	Hold	554,325	–	–	6.08%	6
2021 Q1	$13M	Hold	554,325	–	–	4.34%	8
2020 Q4	$16M	Buy	+554,325	New	+$14M	3.38%	6

Euclidean Capital's CNST Position: Q3 2021 in Review

Euclidean Capital sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 554,325 shares — an estimated $18.7M sold.

Euclidean Capital first reported a position in CNST in Q4 2020 and held it in 3 quarters. The position peaked at $18.7M in Q2 2021. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.

Euclidean Capital reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Euclidean Capital sold 554,325 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $18.7M.
Euclidean Capital first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2020 and held it in 3 quarters.
Euclidean Capital's Constellation Pharmaceuticals, Inc. position peaked at $18.7M in Q2 2021.
0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.

Based on Euclidean Capital's 13F filing for Q3 2021, filed 15 Nov 2021.